Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

Rhea-AI Summary

Celcuity Inc. (NASDAQ:CELC) has announced participation in two upcoming virtual investor conferences. Chairman and CEO Brian Sullivan will present at the 21st Annual Needham Healthcare Conference on April 12, 2022, at 3:45 p.m. ET, with a live webcast available here. He will also present at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 11 a.m. ET, with a live webcast here. Webcasts will be accessible from their website shortly after the events.

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following virtual investor conferences:

• A company presentation at the 21st Annual Needham Healthcare Conference at 3:45 p.m. ET on Tuesday, April 12, 2022. A live webcast will be available using this weblink: https://wsw.com/webcast/needham117/celc/2210269; and
• A company presentation at the Canaccord Genuity Horizons in Oncology Conference at 11 a.m. ET on Thursday, April 14, 2022. A live webcast will be available using this weblink: https://wsw.com/webcast/canaccord74/celc/2411087.

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live events.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

CONTACT:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/696026/Celcuity-to-Participate-in-Upcoming-Needham-and-Canaccord-Genuity-Investor-Conferences

FAQ

What are the conference dates for Celcuity's presentations?

Celcuity will present at the Needham Healthcare Conference on April 12, 2022, and the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022.

Where can I watch the live webcasts for Celcuity's presentations?

The live webcasts for Celcuity's presentations can be accessed on their website or directly through the provided links for each conference.

Who is presenting on behalf of Celcuity at the investor conferences?

Brian Sullivan, Chairman and CEO of Celcuity, will be presenting at both investor conferences.

What is the stock symbol for Celcuity?

The stock symbol for Celcuity is CELC.

What is Celcuity's business focus?

Celcuity is focused on integrated therapeutic and companion diagnostic strategies for treating cancer.